Esperion Therapeutics, Inc. (ESPR)
NASDAQ: ESPR · Real-Time Price · USD
0.9400
+0.0103 (1.11%)
At close: Apr 23, 2025, 4:00 PM
0.9500
+0.0100 (1.06%)
After-hours: Apr 23, 2025, 6:31 PM EDT
Esperion Therapeutics Stock Forecast
ESPR's stock price has decreased by -50.79% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 7 analysts with 12-month price forecasts for Esperion Therapeutics stock have an average target of 6.07, with a low estimate of 2.50 and a high estimate of 16. The average target predicts an increase of 545.74% from the current stock price of 0.94.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Esperion Therapeutics stock from 7 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 0 | 1 | 2 | 2 | 3 | 3 |
| Hold | 0 | 1 | 1 | 1 | 1 | 1 |
| Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 5 | 6 | 6 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Goldman Sachs | Goldman Sachs | Hold Maintains $4 → $3 | Hold | Maintains | $4 → $3 | +219.15% | Apr 17, 2025 |
| Needham | Needham | Strong Buy Reiterates $5 | Strong Buy | Reiterates | $5 | +431.91% | Apr 8, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $16 | Strong Buy | Reiterates | $16 | +1,602.13% | Mar 20, 2025 |
| Citizens Capital Markets | Citizens Capital Markets | Buy Reiterates $4 | Buy | Reiterates | $4 | +325.53% | Mar 5, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $16 | Strong Buy | Reiterates | $16 | +1,602.13% | Mar 4, 2025 |
Financial Forecast
Revenue This Year
349.48M
from 332.31M
Increased by 5.17%
Revenue Next Year
314.33M
from 349.48M
Decreased by -10.06%
EPS This Year
-0.02
from -0.28
EPS Next Year
-0.24
from -0.02
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 441.5M | 383.8M | 639.5M | ||
| Avg | 349.5M | 314.3M | 461.9M | ||
| Low | 240.4M | 204.9M | 353.5M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 32.9% | 9.8% | 103.4% | ||
| Avg | 5.2% | -10.1% | 47.0% | ||
| Low | -27.7% | -41.4% | 12.5% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 0.42 | -0.02 | 0.37 |
| Avg | -0.02 | -0.24 | 0.13 |
| Low | -0.43 | -0.52 | -0.03 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.